Jimmy Lim - Academia.edu (original) (raw)

Papers by Jimmy Lim

Research paper thumbnail of MEDICAL DIGEST

Research paper thumbnail of Clinical predictors of stent thrombosis in the “real world” drug-eluting stent era

International Journal of Cardiology, 2010

Background: Drug-eluting stents (DESs) are effective in reducing restenosis and the need for repe... more Background: Drug-eluting stents (DESs) are effective in reducing restenosis and the need for repeat revascularization procedures in patients who undergo percutaneous coronary intervention (PCI). There is however an increased concern with the safety of DES with regard to stent thrombosis (ST). We examined the incidence of ST among patients who received DES and determined the clinical predictors. Methods: All patients who underwent PCI in our centre were prospectively enrolled in a cardiovascular database. All cases of ST, as defined by 2006 Academic Research Consortium (ARC) hierarchical classification as definite and probable, from August 2002 to August 2006 were reviewed and analyzed. The clinical, angiographic and procedural characteristics of patients who developed ST were compared with those who did not. Results: The study population comprised 1580 patients who received DES implantation. The cumulative incidence of ST was 1.5%: acute ST 0.2%, subacute ST 0.9%, late ST 0.2% and very late ST 0.2%. Mortality and myocardial infarction occurred in 16% and 84% of patients, respectively, as a consequence of ST. Multivariate analysis showed that patients presenting with cardiogenic shock, acute coronary syndrome, presence of multivessel disease, impaired baseline TIMI flow and higher number of stents implanted per lesion were predictive of ST. Conclusion: The incidence of DES ST in our 'real world' registry was low. There were clinical and angiographic characteristics identified as independent predictors of ST.

Research paper thumbnail of Long-term follow-up after percutaneous coronary intervention in patients with systemic lupus erythematosus

International Journal of Cardiology, 2008

Research paper thumbnail of CYPHER versus TAXUS stent for bifurcation lesions beyond 30 days—long-term follow-up results

International Journal of Cardiology, 2007

Research paper thumbnail of Type A aortic dissection: a hidden and lethal cause for failed thrombolytic treatment in acute myocardial infarction

Research paper thumbnail of Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate to long-term clinical follow-up

American Heart Journal, 2008

Aims We assessed the use of the endothelial progenitor cell (EPC) capture stent in primary percut... more Aims We assessed the use of the endothelial progenitor cell (EPC) capture stent in primary percutaneous intervention in ST-elevation myocardial infarction (STEMI).

Research paper thumbnail of Incidence, predictors, and outcomes of device failure of X-sizer thrombectomy: Real-world experience of 200 cases in 5 years

American Heart Journal, 2007

Background Clinical studies have evaluated the safety and efficacy of adjunctive X-sizer (EndiCOR... more Background Clinical studies have evaluated the safety and efficacy of adjunctive X-sizer (EndiCOR Inc, San Clemente, CA) in percutaneous coronary intervention (PCI). However, patient and lesion subsets were highly selected, and extrapolation of the results to daily practice is problematic. Methods X-sizer thrombectomy was performed in 200 procedures from August 2000 to July 2005. The indications for the procedures were primary PCI in 71%. Device failure was defined as the occurrence of 1 or more of the following conditions: (a) failure of the X-sizer to reach the target segment, (b) failure to achieve final thrombolysis in myocardial infarction 3 flow, (c) slow flow or no-reflow, (d) distal embolization, and (e) coronary perforation.

Research paper thumbnail of Type A aortic dissection: a hidden and lethal cause for failed thrombolytic treatment in acute myocardial infarction

Research paper thumbnail of A novel drug-eluting stent using bioabsorbable polymer technology: Two-year follow-up of the CURAMI registry

International Journal of Cardiology, 2009

There are safety concerns on drug-eluting stents (DESs) using durable polymer. The long-term outc... more There are safety concerns on drug-eluting stents (DESs) using durable polymer. The long-term outcome of next generation DESs using bioabsorbable polymer technology remains unknown.From March to June, 2005, a novel sirolimus-eluting (170 μg/cm2), bioabsorbable polymer (PLA and PLGA, eroded over 45 days) coated stent was implanted for treatment of acute myocardial infarction (AMI) in 49 patients (male 86%, age 55 + 10 years, diabetes 31%). All culprits were de novo lesions in the native coronary artery. On discharge, aspirin and clopidogrel for 3 months followed by life-long aspirin were prescribed. Angiographic follow-up was performed at 8 months. Clinical follow-up was performed at 4, 9 and 24 months.Angiographic success rate was 100%. In-hospital adverse events consisted of 1 death (2%). All except one patient (due to aspirin allergy) were compliant to the 3 months dual antiplatelet therapy, and there was no adverse event during this period. One patient developed re-infarction in another coronary territory at 6 months. Twenty-seven patients (56%) underwent 8-month angiographic follow-up (Table 3). At 24 months, 6 patients had 7 major adverse cardiac events (12.2%, 1 death, 2 re-infarctions and 4 target lesion revascularizations). There were no incidences of subacute or late stent thrombosis.The Cura stent, using bioabsorbable polymer technology, appears to be safe at 2 years follow-up. Although the angiographic follow-up parameters were unfavorable, this report paves the way for further studies on DES using bioabsorbable polymer technology.

Research paper thumbnail of MEDICAL DIGEST

Research paper thumbnail of Clinical predictors of stent thrombosis in the “real world” drug-eluting stent era

International Journal of Cardiology, 2010

Background: Drug-eluting stents (DESs) are effective in reducing restenosis and the need for repe... more Background: Drug-eluting stents (DESs) are effective in reducing restenosis and the need for repeat revascularization procedures in patients who undergo percutaneous coronary intervention (PCI). There is however an increased concern with the safety of DES with regard to stent thrombosis (ST). We examined the incidence of ST among patients who received DES and determined the clinical predictors. Methods: All patients who underwent PCI in our centre were prospectively enrolled in a cardiovascular database. All cases of ST, as defined by 2006 Academic Research Consortium (ARC) hierarchical classification as definite and probable, from August 2002 to August 2006 were reviewed and analyzed. The clinical, angiographic and procedural characteristics of patients who developed ST were compared with those who did not. Results: The study population comprised 1580 patients who received DES implantation. The cumulative incidence of ST was 1.5%: acute ST 0.2%, subacute ST 0.9%, late ST 0.2% and very late ST 0.2%. Mortality and myocardial infarction occurred in 16% and 84% of patients, respectively, as a consequence of ST. Multivariate analysis showed that patients presenting with cardiogenic shock, acute coronary syndrome, presence of multivessel disease, impaired baseline TIMI flow and higher number of stents implanted per lesion were predictive of ST. Conclusion: The incidence of DES ST in our 'real world' registry was low. There were clinical and angiographic characteristics identified as independent predictors of ST.

Research paper thumbnail of Long-term follow-up after percutaneous coronary intervention in patients with systemic lupus erythematosus

International Journal of Cardiology, 2008

Research paper thumbnail of CYPHER versus TAXUS stent for bifurcation lesions beyond 30 days—long-term follow-up results

International Journal of Cardiology, 2007

Research paper thumbnail of Type A aortic dissection: a hidden and lethal cause for failed thrombolytic treatment in acute myocardial infarction

Research paper thumbnail of Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate to long-term clinical follow-up

American Heart Journal, 2008

Aims We assessed the use of the endothelial progenitor cell (EPC) capture stent in primary percut... more Aims We assessed the use of the endothelial progenitor cell (EPC) capture stent in primary percutaneous intervention in ST-elevation myocardial infarction (STEMI).

Research paper thumbnail of Incidence, predictors, and outcomes of device failure of X-sizer thrombectomy: Real-world experience of 200 cases in 5 years

American Heart Journal, 2007

Background Clinical studies have evaluated the safety and efficacy of adjunctive X-sizer (EndiCOR... more Background Clinical studies have evaluated the safety and efficacy of adjunctive X-sizer (EndiCOR Inc, San Clemente, CA) in percutaneous coronary intervention (PCI). However, patient and lesion subsets were highly selected, and extrapolation of the results to daily practice is problematic. Methods X-sizer thrombectomy was performed in 200 procedures from August 2000 to July 2005. The indications for the procedures were primary PCI in 71%. Device failure was defined as the occurrence of 1 or more of the following conditions: (a) failure of the X-sizer to reach the target segment, (b) failure to achieve final thrombolysis in myocardial infarction 3 flow, (c) slow flow or no-reflow, (d) distal embolization, and (e) coronary perforation.

Research paper thumbnail of Type A aortic dissection: a hidden and lethal cause for failed thrombolytic treatment in acute myocardial infarction

Research paper thumbnail of A novel drug-eluting stent using bioabsorbable polymer technology: Two-year follow-up of the CURAMI registry

International Journal of Cardiology, 2009

There are safety concerns on drug-eluting stents (DESs) using durable polymer. The long-term outc... more There are safety concerns on drug-eluting stents (DESs) using durable polymer. The long-term outcome of next generation DESs using bioabsorbable polymer technology remains unknown.From March to June, 2005, a novel sirolimus-eluting (170 μg/cm2), bioabsorbable polymer (PLA and PLGA, eroded over 45 days) coated stent was implanted for treatment of acute myocardial infarction (AMI) in 49 patients (male 86%, age 55 + 10 years, diabetes 31%). All culprits were de novo lesions in the native coronary artery. On discharge, aspirin and clopidogrel for 3 months followed by life-long aspirin were prescribed. Angiographic follow-up was performed at 8 months. Clinical follow-up was performed at 4, 9 and 24 months.Angiographic success rate was 100%. In-hospital adverse events consisted of 1 death (2%). All except one patient (due to aspirin allergy) were compliant to the 3 months dual antiplatelet therapy, and there was no adverse event during this period. One patient developed re-infarction in another coronary territory at 6 months. Twenty-seven patients (56%) underwent 8-month angiographic follow-up (Table 3). At 24 months, 6 patients had 7 major adverse cardiac events (12.2%, 1 death, 2 re-infarctions and 4 target lesion revascularizations). There were no incidences of subacute or late stent thrombosis.The Cura stent, using bioabsorbable polymer technology, appears to be safe at 2 years follow-up. Although the angiographic follow-up parameters were unfavorable, this report paves the way for further studies on DES using bioabsorbable polymer technology.